[Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
Ariyoshi
Yusuke
Y
yusuke.ariyoshi@shionogi.co.jp
Mizumoto
Keigo
K
D047228:Angiotensin II Type 1 Receptor Blockers / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D000077405:Irbesartan; D007674:Kidney Diseases / Q000150:complications; D016032:Randomized Controlled Trials as Topic; D013777:Tetrazoles / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D003692:Delayed-Action Preparations; D013777:Tetrazoles; D000077405:Irbesartan